Search research articles
Contact Us
Filters
Showing results (21-30 of 111) with videos related to
Page
of 12
Sort By:
Neuroreport
|
October 6, 2001
Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses
A J Law, J F Deakin
Journal of Psychopharmacology (Oxford, England)
|
January 5, 2002
Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study
S M Dursun, J F Deakin
Journal of Psychopharmacology (Oxford, England)
|
January 28, 2012
5-HT and mechanisms of defence. Author's response
J F Deakin, F G Graeff
Neuroscience Letters
|
July 17, 2009
Periaqueductal grey lesions reduce morphine analgesia in the rat
J O Dostrovsky, J F Deakin
Nature
|
May 22, 1980
Brain noradrenaline depletion prevents ECS-induced enhancement of serotonin- and dopamine-mediated behaviour
A R Green, J F Deakin
British Journal of Pharmacology
|
March 1, 1977
Role of tryptaminergic mechanisms in the elements of the behavioural syndrome evoked by tryptophan and a monoamine oxidase inhibitor [proceedings]
T J Crow, J F Deakin
Neuropharmacology
|
February 1, 1981
The differential neurochemical bases of the behaviours elicited by serotonergic agents and by the combination of a monoamine oxidase inhibitor and L-DOPA
J F Deakin, M R Dashwood
Journal of Psychiatric Research
|
March 1, 1997
A two-process theory of schizophrenia: evidence from studies in post-mortem brain
J F Deakin, M D Simpson
Neuroscience Letters
|
October 10, 1985
Cortical serotonin receptor subtypes after lesion of ascending cholinergic neurones in rat
A J Cross, J F Deakin
Journal of Neural Transmission (Vienna, Austria : 1996)
|
January 1, 1996
Increased density of entorhinal glutamate-immunoreactive vertical fibers in schizophrenia
D Longson, J F Deakin, F M Benes
Page
of 12
Search research articles
Search
Showing results (21-30 of 111) with videos related to
Sort By:
Page
of 12
Neuroreport
|
October 6, 2001
Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses
A J Law, J F Deakin
Journal of Psychopharmacology (Oxford, England)
|
January 5, 2002
Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study
S M Dursun, J F Deakin
Journal of Psychopharmacology (Oxford, England)
|
January 28, 2012
5-HT and mechanisms of defence. Author's response
J F Deakin, F G Graeff
Neuroscience Letters
|
July 17, 2009
Periaqueductal grey lesions reduce morphine analgesia in the rat
J O Dostrovsky, J F Deakin
Nature
|
May 22, 1980
Brain noradrenaline depletion prevents ECS-induced enhancement of serotonin- and dopamine-mediated behaviour
A R Green, J F Deakin
British Journal of Pharmacology
|
March 1, 1977
Role of tryptaminergic mechanisms in the elements of the behavioural syndrome evoked by tryptophan and a monoamine oxidase inhibitor [proceedings]
T J Crow, J F Deakin
Neuropharmacology
|
February 1, 1981
The differential neurochemical bases of the behaviours elicited by serotonergic agents and by the combination of a monoamine oxidase inhibitor and L-DOPA
J F Deakin, M R Dashwood
Journal of Psychiatric Research
|
March 1, 1997
A two-process theory of schizophrenia: evidence from studies in post-mortem brain
J F Deakin, M D Simpson
Neuroscience Letters
|
October 10, 1985
Cortical serotonin receptor subtypes after lesion of ascending cholinergic neurones in rat
A J Cross, J F Deakin
Journal of Neural Transmission (Vienna, Austria : 1996)
|
January 1, 1996
Increased density of entorhinal glutamate-immunoreactive vertical fibers in schizophrenia
D Longson, J F Deakin, F M Benes
Page
of 12